Circio Holding ASA (“Circio” or “the Company”) announced, on the 11th of November 2026, a research collaboration with Nasdaq-listed Solid Biosciences Inc. (“Solid”) to combine Circio’s circVec expression platform with POLARIS-101, Solid’s proprietary next-generation AAV capsid, for systemic gene therapy in genetic heart disease. Under the agreement, Circio will generate constructs based on its latest generation 5 circVec design, which Solid will package using POLARIS-101 and its dual plasmid manufacturing platform. The parties will then jointly characterize and test the resulting vectors both in vitro and in vivo, with successful candidates evaluated further and advanced into preclinical development. No financial terms are disclosed.
In summary, Analyst Group considers the Solid Biosciences agreement one of the most substantive additions to Circio’s delivery network to date. High vector doses remain the central bottleneck in systemic cardiac gene therapy, driving both toxicity risk and manufacturing cost, and the collaboration addresses that constraint from two directions. Here, circVec 5.2, which has shown approx. 200-fold higher gene expression than conventional AAV vectors in heart, raises output per cell, while POLARIS-101, a capsid already dosed systemically in patients, is engineered to direct more of the dose to cardiac muscle and less to the liver. The work nevertheless sits at an early stage, carries no disclosed financial terms, and positions any successful candidate at the entry to preclinical development rather than near the clinic. Analyst Group still considers the signal meaningful already today, as circVec has been chosen as the expression component by a clinical-stage developer with cardiac programs of its own, a counterparty profile from which a licensing relationship could realistically develop over time.
Read Analyst Group’s comment here
About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of a comment on Circio Holding. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.